A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Highlights of the NCCN Oncology Research Program
The Journal of the National Comprehensive Cancer Network
This is an open-label, multicenter, phase II study of trifluridine/tipiracil (FTD/TPI) administered with oxaliplatin before chemoradiation in patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). Patients meeting inclusion criteria will receive 3 cycles of FTD/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatindoi:10.6004/jnccn.2020.0014 fatcat:etsau6bzrffdfkp3zbaddxj65i